ALLO
Allogene Therapeutics, Inc.
$2.28
+0.44%
2026-05-08
About Allogene Therapeutics, Inc.
Allogene Therapeutics, Inc. a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer and autoimmune diseases. It develops a pipeline of multiple allogeneic CAR T cell product candidates utilizing protein engineering, gene editing, gene insertion, and advanced proprietary T cell manufacturing technologies. The company is also developing cemacabtagene ansegedleucel (cema-cel), an engineered allogeneic CAR T cell product candidate that targets CD19 for the treatment of large B-cell lymphoma (LBCL). In addition, it develops ALLO-316, an engineered allogeneic CAR T cell product candidate that targets CD70 to treat renal cell carcinoma (RCC); and ALLO-329, an engineered allogeneic CAR T cell product candidate that targets both CD19 and CD70 for the treatment of autoimmune diseases (AID), such as systemic lupus erythematosus (SLE), idiopathic inflammatory myopathies (IIM), and systemic sclerosis (SSc). The company was incorporated in 2017 and is headquartered in South San Francisco, California.
Key Fundamentals
Forward P/E
-3.26
EPS (TTM)
$-0.87
ROE
-53.4%
Profit Margin
0.0%
Debt/Equity
28.46
Price/Book
1.78
Beta
0.46
Market Cap
$784.9M
Avg Volume (10D)
6.1M
Recent Breakout Signals
No recent breakout signals detected for ALLO.
Recent Price Range (60 Days)
60D High
$4.46
60D Low
$1.56
Avg Volume
9.3M
Latest Close
$2.28
Get breakout alerts for ALLO
Sign up for Breakout Scanner to receive daily notifications when ALLO triggers breakout signals. Build custom AI screeners and backtest strategies.
Start Free Trial7-day free trial. No card required.
Allogene Therapeutics, Inc. (ALLO) is listed on the NASDAQ (NASDAQ). Breakout Scanner monitors ALLO daily for breakout patterns including long-term ceiling breakouts, momentum breakouts, and near-breakout watch setups. ALLO operates in the Healthcare sector within the Biotechnology industry. Data is provided for informational purposes only and does not constitute financial advice.